Study Title: The CompassHER2 Trials (Comprehensive Use of Pathological Response Assessment to Optimize Therapy in HER2 Positive Breast Cancer): CompassHer2 Residual Disease (RD), A Double Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Brescia, Frank, at bresciaf@musc.edu.Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu.Trial opened at the following institutions: Medical University of South Carolina